Joel A Sincavage

Array ( [id] => 16728195 [patent_doc_number] => 20210095342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => FUNCTIONAL TARGETS OF MIR-6891-5P & APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 16/099243 [patent_app_country] => US [patent_app_date] => 2017-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26481 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16099243 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14277229 [patent_doc_number] => 20190135899 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => DNA Monoclonal Antibodies Targeting Influenza Virus [patent_app_type] => utility [patent_app_number] => 16/098921 [patent_app_country] => US [patent_app_date] => 2017-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23981 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16098921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11936755 [patent_doc_number] => 20170240905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'IMPAIRED WOUND HEALING COMPOSITION AND TREATMENTS' [patent_app_type] => utility [patent_app_number] => 15/583898 [patent_app_country] => US [patent_app_date] => 2017-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 22127 [patent_no_of_claims] => 61 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15583898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13026813 [patent_doc_number] => 10036023 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-31 [patent_title] => Treatment of disease by modulation of SIRT6 [patent_app_type] => utility [patent_app_number] => 15/498504 [patent_app_country] => US [patent_app_date] => 2017-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 15 [patent_no_of_words] => 5965 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15498504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17251362 [patent_doc_number] => 11186838 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-30 [patent_title] => LNCRNA MEG3 for therapy and diagnosis of cardiac remodelling [patent_app_type] => utility [patent_app_number] => 16/098793 [patent_app_country] => US [patent_app_date] => 2017-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 18 [patent_no_of_words] => 18663 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 173 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16098793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15264711 [patent_doc_number] => 20190381089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => OLIGONUCLEOTIDES TO TREAT EYE DISEASE [patent_app_type] => utility [patent_app_number] => 16/096038 [patent_app_country] => US [patent_app_date] => 2017-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11784 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16096038 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17378344 [patent_doc_number] => 11236342 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => Secretory immunoglobulin a (sIgA)-binding nucleic acid molecule, sIgA analysis sensor, and sIgA analysis method [patent_app_type] => utility [patent_app_number] => 16/333293 [patent_app_country] => US [patent_app_date] => 2017-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 13 [patent_no_of_words] => 11570 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16333293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13749079 [patent_doc_number] => 10167472 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-01 [patent_title] => PME-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition [patent_app_type] => utility [patent_app_number] => 15/487548 [patent_app_country] => US [patent_app_date] => 2017-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 51 [patent_no_of_words] => 21492 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15487548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13168409 [patent_doc_number] => 10100310 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-16 [patent_title] => Modulation of prekallikrein (PKK) expression [patent_app_type] => utility [patent_app_number] => 15/484858 [patent_app_country] => US [patent_app_date] => 2017-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 66054 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15484858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12206057 [patent_doc_number] => 20180051283 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-22 [patent_title] => 'COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION' [patent_app_type] => utility [patent_app_number] => 15/472110 [patent_app_country] => US [patent_app_date] => 2017-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 31672 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15472110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15574479 [patent_doc_number] => 10577607 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-03 [patent_title] => Modulation of DYRK1B expression [patent_app_type] => utility [patent_app_number] => 16/085140 [patent_app_country] => US [patent_app_date] => 2017-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25531 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16085140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16290346 [patent_doc_number] => 10767183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-08 [patent_title] => Combination vectors and methods for treating cancer [patent_app_type] => utility [patent_app_number] => 16/083384 [patent_app_country] => US [patent_app_date] => 2017-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 19 [patent_no_of_words] => 19517 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16083384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17135031 [patent_doc_number] => 11136577 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-05 [patent_title] => Methods and compositions for inhibiting PMP22 expression [patent_app_type] => utility [patent_app_number] => 16/083086 [patent_app_country] => US [patent_app_date] => 2017-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17527 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16083086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16771114 [patent_doc_number] => 10982209 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Read through of truncated proteins in premature termination codon diseases by suppressor tRNAs [patent_app_type] => utility [patent_app_number] => 16/083772 [patent_app_country] => US [patent_app_date] => 2017-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6326 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16083772 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14794485 [patent_doc_number] => 10400237 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-03 [patent_title] => Compositions and methods for treating vascular disorders [patent_app_type] => utility [patent_app_number] => 15/448225 [patent_app_country] => US [patent_app_date] => 2017-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 36 [patent_no_of_words] => 32623 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15448225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14277915 [patent_doc_number] => 20190136242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => PAN-GENOTYPIC AGENTS AGAINST INFLUENZA VIRUS AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/081818 [patent_app_country] => US [patent_app_date] => 2017-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20187 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16081818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13902381 [patent_doc_number] => 20190040395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => MODULATORS OF KLK3 ERNA [patent_app_type] => utility [patent_app_number] => 16/074744 [patent_app_country] => US [patent_app_date] => 2017-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4276 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16074744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16491220 [patent_doc_number] => 10857238 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-08 [patent_title] => Nano-enhanced optical delivery of exogenous molecules to cells and tissues [patent_app_type] => utility [patent_app_number] => 16/074041 [patent_app_country] => US [patent_app_date] => 2017-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 47 [patent_no_of_words] => 14426 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16074041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15309503 [patent_doc_number] => 10519442 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-31 [patent_title] => Twist signaling inhibitor compositions and methods of using the same [patent_app_type] => utility [patent_app_number] => 15/430372 [patent_app_country] => US [patent_app_date] => 2017-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 95 [patent_no_of_words] => 56894 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15430372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12199900 [patent_doc_number] => 09902959 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-27 [patent_title] => 'Treatment of Frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN' [patent_app_type] => utility [patent_app_number] => 15/423020 [patent_app_country] => US [patent_app_date] => 2017-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 28504 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15423020 [rel_patent_id] =>[rel_patent_doc_number] =>)